BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2012-08-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.1203326109PMID 22869732PMCID PMC3427093
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of DNA double strand break repair pathways

  2013cited by this paper
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  2010cited by this paper
• Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

  2010cited by this paper
• BRCA1 and its toolbox for the maintenance of genome integrity

  2010cited by this paper
• Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination.

  2010cited by this paper
• PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2

  2009cited by this paper
• Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90

  2009cited by this paper
• Update on Hsp90 inhibitors in clinical trial.

  2009cited by this paper
• Cisplatin abrogates the geldanamycin-induced heat shock response

  2008cited by this paper
• Targeting base excision repair for chemosensitization.

  2008cited by this paper
• Drug resistance caused by reversion mutation.

  2008cited by this paper
• Rapid Recruitment of BRCA1 to DNA Double-Strand Breaks Is Dependent on Its Association with Ku80

  2008cited by this paper
• Loss of CHK1 function impedes DNA damage-induced FANCD2 monoubiquitination but normalizes the abnormal G2 arrest in Fanconi anemia.

  2008cited by this paper
• Cell Cycle-dependent Complex Formation of BRCA1·CtIP·MRN Is Important for DNA Double-strand Break Repair*

  2008cited by this paper
• Regulation of DNA double-strand break repair pathway choice

  2008cited by this paper
• Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

  2008cited by this paper
• Hsp90 regulates the Fanconi anemia DNA damage response pathway.

  2007influential reference
• BRCA1 dysfunction in sporadic basal-like breast cancer

  2007cited by this paper
• p53, BRCA1 and breast Cancer chemoresistance.

  2007cited by this paper
• Inhibition of Hsp90: A Multitarget Approach to Radiosensitization

  2007cited by this paper
• Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining.

  2006cited by this paper
• Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.

  2006influential reference
• Hsp90 inhibitors: Small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation

  2006cited by this paper
• BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance

  2006cited by this paper
• Inhibition of hsp90 compromises the DNA damage response to radiation.

  2006influential reference
• HSP90 and the chaperoning of cancer

  2005cited by this paper
• Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair.

  2005cited by this paper
• Ubiquitination and Proteasomal Degradation of the BRCA1 Tumor Suppressor Is Regulated during Cell Cycle Progression*

  2004cited by this paper
• Breast Cancer Risk and the DNA Double-Strand Break End-Joining Capacity of Nonhomologous End-Joining Genes Are Affected by BRCA1

  2004cited by this paper
• Role of BRCA1 in heat shock response

  2003cited by this paper
• The Fanconi anaemia/BRCA pathway

  2003cited by this paper
• Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2

  2003cited by this paper
• Hsp90 Inhibition Depletes Chk1 and Sensitizes Tumor Cells to Replication Stress*

  2003cited by this paper
• Loss of Bard1, the Heterodimeric Partner of the Brca1 Tumor Suppressor, Results in Early Embryonic Lethality and Chromosomal Instability

  2003cited by this paper
• The BRCA1 and BARD1 association with the RNA polymerase II holoenzyme.

  2002cited by this paper
• BRCA1 interacts directly with the Fanconi anemia protein FANCA.

  2002cited by this paper
• BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage

  2002cited by this paper
• Absence of major defects in non-homologous DNA end joining in human breast cancer cell lines

  2002cited by this paper
• Functional communication between endogenous BRCA1 and its partner, BARD1, during Xenopus laevis development

  2001cited by this paper
• REDUCED EXPRESSION OF THE BRCA1 GENE AND INCREASED CHROMOSOMAL INSTABILITY IN MCF‐7 CELL LINE

  2001cited by this paper
• The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin*

  2000cited by this paper
• Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks.

  1999cited by this paper
• Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response.

  1999cited by this paper
• BRCA1 Expression Restores Radiation Resistance in BRCA1-defective Cancer Cells through Enhancement of Transcription-coupled DNA Repair*

  1999cited by this paper
• BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II).

  1998cited by this paper
• Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression

  1995cited by this paper
• Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families

  1994cited by this paper
• Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

  1994cited by this paper
• Linkage of early-onset familial breast cancer to chromosome 17q21.

  1990cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• Analysis of combined drug effects: a new look at a very old problem

  1983cited by this paper

• Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responses

  2025cites this paper
• A randomized, multicenter, open-label phase III trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer: a rationale and study design of the KOV-HIPEC-02 trial.

  2025cites this paper
• Inhibition of GSK3β is synthetic lethal with FHIT loss in lung cancer by blocking homologous recombination repair

  2025cites this paper
• Therapy resistance: modulating evolutionarily conserved heat shock protein machinery in cancer.

  2025cites this paper
• DualMarker: A Multi-Source Fusion Identification Method for Prognostic Biomarkers of Breast Cancer Based on Dual-Layer Heterogeneous Network

  2025cites this paper
• Pimitespib, an HSP90 Inhibitor, Enhances the Efficacy of PARP Inhibitors in PARP Inhibitor‐Insensitive Breast Cancer Cells

  2025cites this paper
• Combination Strategies with HSP90 Inhibitors in Cancer Therapy: Mechanisms, Challenges, and Future Perspectives

  2025cites this paper
• Berberine overcomes paclitaxel resistance in Triple-Negative Breast Cancer by inhibiting HSP90-mediated BRCA1 phosphorylation.

  2025cites this paper
• At the nucleus of cancer: how the nuclear envelope controls tumor progression

  2025cites this paper
• Advancements in Clinical Research and Emerging Therapies for Triple-Negative Breast Cancer Treatment.

  2024cites this paper
• The CDK12–BRCA1 signaling axis mediates dinaciclib‐associated radiosensitivity through p53‐mediated cellular senescence

  2024cites this paper
• Update on Combination Strategies of PARP Inhibitors

  2024cites this paper
• 1G6‐D7 Inhibits Homologous Recombination Repair by Targeting Extracellular HSP90α to Promote Apoptosis in Non–Small Cell Lung Cancer

  2024cites this paper
• Personalized Systemic Therapies in Hereditary Cancer Syndromes

  2023cites this paper
• Rational Combinations of PARP Inhibitors with HRD-Inducing Molecularly Targeted Agents.

  2023cites this paper
• A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer

  2023cites this paper
• Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy.

  2023cites this paper
• Ailanthone synergizes with PARP1 inhibitor in tumour growth inhibition through crosstalk of DNA repair pathways in gastric cancer

  2023cites this paper
• Does overproduction of chaperone proteins favour the repair of DNA injuries induced by oxidative stress? (Mini review)

  2023cites this paper
• Enhanced efficacy of combined fluzoparib and chidamide targeting in natural killer/T-cell lymphoma

  2023cites this paper
• PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers

  2022influential citation
• Mitigating the detrimental effects of heat stress in poultry through thermal conditioning and nutritional manipulation.

  2022cites this paper
• The Role of Hsp90-R2TP in Macromolecular Complex Assembly and Stabilization

  2022cites this paper
• Emerging Link between Tsc1 and FNIP Co-Chaperones of Hsp90 and Cancer

  2022cites this paper
• ATF6 prevents DNA damage and cell death in colon cancer cells undergoing ER stress

  2022cites this paper
• CAR T Cell Locomotion in Solid Tumor Microenvironment

  2022cites this paper
• Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors

  2022cites this paper
• Benzo(a)pyrene regulates chaperone-mediated autophagy via heat shock protein 90

  2022cites this paper
• Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial

  2022cites this paper
• Hsp90 inhibition sensitizes DLBCL cells to cisplatin

  2022cites this paper
• Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment.

  2022cites this paper
• PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies

  2022cites this paper
• Molecular chaperones in DNA repair mechanisms: Role in genomic instability and proteostasis in cancer.

  2022cites this paper
• Lamin-A interacting protein Hsp90 is required for DNA damage repair and chemoresistance of ovarian cancer cells

  2021cites this paper
• Celastrol and Triptolide Suppress Stemness in Triple Negative Breast Cancer: Notch as a Therapeutic Target for Stem Cells

  2021cites this paper
• Pharmacological inhibition of HSP90 radiosensitizes HNSCC xenograft by inhibition of DNA damage repair, nucleotide metabolism, and radiation-induced tumor vasculogenesis.

  2021cites this paper
• Identifying intracellular signaling modules and exploring pathways associated with breast cancer recurrence

  2021cites this paper
• The N-terminal MYB domains affect the stability and folding aspects of Arabidopsis thaliana MYB4 transcription factor under thermal stress

  2021cites this paper
• Determinants of Homologous Recombination Deficiency in Pancreatic Cancer

  2021cites this paper
• Repurposing drugs as novel triple negative breast cancer therapeutics.

  2021cites this paper
• Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours

  2021cites this paper
• Damage-associated molecular patterns in tumor radiotherapy.

  2020cites this paper
• Wirkung des HSP90-Inhibitors AUY922 in Ewing-Sarkomzellen

  2020cites this paper
• Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.

  2020cites this paper
• Pharmacological ascorbate induces ‘BRCAness’ and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer

  2020cites this paper
• Title: Ganetespib in combination with pemetrexed-platinum chemotherapy in patients with pleural Mesothelioma (MESO-02): A phase Ib trial

  2020cites this paper
• Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma

  2020cites this paper
• LESSONS LEARNED FROM UNDERSTANDING CHEMOTHERAPY RESISTANCE IN EPITHELIAL TUBO-OVARIAN CARCINOMA FROM BRCA1 AND BRCA2 MUTATION CARRIERS.

  2020cites this paper
• PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

  2020cites this paper
• Ganetespib in Combination with Pemetrexed–Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial

  2020cites this paper
• Recent update on discovery and development of Hsp90 inhibitors as senolytic agents.

  2020cites this paper
• Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer

  2019cites this paper
• HSP90: A Key Player in Metal-Induced Carcinogenesis?

  2019cites this paper
• Recent study of dual HDAC/PARP inhibitor for the treatment of tumor.

  2019cites this paper
• Heat shock proteins create a signature to predict the clinical outcome in breast cancer

  2019cites this paper
• Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis

  2019cites this paper
• Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition

  2019cites this paper
• Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells

  2019cites this paper
• Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.

  2019cites this paper
• MiR-210-3p protects endometriotic cells from oxidative stress-induced cell cycle arrest by targeting BARD1

  2019cites this paper
• 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition

  2019cites this paper
• Recent therapeutic trends and promising targets in triple negative breast cancer.

  2019cites this paper
• The Hsp90 Molecular Chaperone Regulates the Transcription Factor Network Controlling Chromatin Accessibility.

  2019cites this paper
• Small intestinal neuroendocrine tumours - Disease models, tumour development, and remedy

  2019cites this paper
• Heat-shock proteins: chaperoning DNA repair

  2019cites this paper
• Non-homologous end joining is more important than proton linear energy transfer in dictating cell death.

  2019influential citation
• Role of the Molecular Chaperones Hsp70 and Hsp90 in the DNA Damage Response

  2019cites this paper
• Targeting vulnerabilities through inhibiting the valosin-containing protein (VCP/p97) in ovarian cancer

  2018cites this paper
• ATM Is Required for the Prolactin-Induced HSP90-Mediated Increase in Cellular Viability and Clonogenic Growth After DNA Damage

  2018cites this paper
• Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation

  2018cites this paper
• Hexavalent chromium, a lung carcinogen, confers resistance to thermal stress and interferes with heat shock protein expression in human bronchial epithelial cells

  2018cites this paper
• Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer

  2018cites this paper
• Heat shock proteins and DNA repair mechanisms: an updated overview

  2018cites this paper
• Hyperthermia‐mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer

  2018cites this paper
• Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer

  2018cites this paper
• Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.

  2018cites this paper
• Hsp90 Is Essential for Chl1-Mediated Chromosome Segregation and Sister Chromatid Cohesion

  2018cites this paper
• Hsp90 inhibitors as senolytic drugs to extend healthy aging

  2018cites this paper
• Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer.

  2018cites this paper
• MiR-584-5p potentiates vincristine and radiation response by inducing spindle defects and DNA damage in medulloblastoma

  2018cites this paper
• Targeting the lysosome by an aminomethylated Riccardin D triggers DNA damage through cathepsin B‐mediated degradation of BRCA1

  2018cites this paper
• HSP90 Inhibition Enhances the Anti-Tumor Efficacy of Combination Chemo Immunotherapy Targeting DNA Repair Proteins

  2017cites this paper
• Cdc7-Dbf4-mediated phosphorylation of HSP90-S164 stabilizes HSP90-HCLK2-MRN complex to enhance ATR/ATM signaling that overcomes replication stress in cancer

  2017cites this paper
• Interstrand Crosslink Repair as a Target for HDAC Inhibition.

  2017cites this paper
• Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas

  2017cites this paper
• Chaperoning the Cancer: The Proteostatic Functions of the Heat Shock Proteins in Cancer.

  2017cites this paper
• Boosting the effects of hyperthermia-based anticancer treatments by HSP90 inhibition

  2017cites this paper
• Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery

  2017cites this paper
• PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.

  2017cites this paper
• Reverse the Resistance to PARP Inhibitors

  2017influential citation
• HSP90-inhibitor Ganetesbip potentiates radiosensitizing and chemosensitizing effects of hyperthermia

  2017cites this paper
• Hsp90 induces increased genomic instability toward DNA-damaging agents by tuning down RAD53 transcription

  2016cites this paper
• CHK2–BRCA1 tumor-suppressor axis restrains oncogenic Aurora-A kinase to ensure proper mitotic microtubule assembly

  2016cites this paper
• Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells

  2016cites this paper
• HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.

  2016cites this paper
• The putative oncogene CEP72 inhibits the mitotic function of BRCA1 and induces chromosomal instability

  2016cites this paper
• Biology and Management of Patients With Triple-Negative Breast Cancer.

  2016cites this paper
• Identification Of Novel Therapeutic Small-Molecule Inhibitors Of Dna Double-Stranded Break Repair

  2016cites this paper
• Aneuploidy impairs protein folding and genome integrity in human cells

  2016cites this paper
• Network biology identifies novel apoptosis-related proteins and synergistic drug combinations in breast cancer

  2016cites this paper